SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-026572
Filing Date
2022-10-18
Accepted
2022-10-18 17:09:54
Documents
16
Period of Report
2022-10-18
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20221018.htm   iXBRL 8-K 43370
2 EX-99.1 exhibit991-oct2022denali8xk.htm EX-99.1 9792
3 EX-99.2 exhibit992-oct2022denali8xk.htm EX-99.2 1988
4 EX-99.3 exhibit993-oct2022denali8xk.htm EX-99.3 426928
8 denali_txlogox02a.jpg GRAPHIC 604226
  Complete submission text file 0001628280-22-026572.txt   1555311

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20221018.xsd EX-101.SCH 1932
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20221018_lab.xml EX-101.LAB 23832
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20221018_pre.xml EX-101.PRE 12528
10 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20221018_htm.xml XML 10926
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 221316541
SIC: 2836 Biological Products, (No Diagnostic Substances)